myBiometry

myBiometry is a health technology company focused on improving asthma management through innovative technology. Their patented sensor and device measures airway inflammation via fractional exhaled nitric oxide (FeNO) to predict and prevent asthma attacks. The company's app gathers clinical and environmental risk factors to determine the root cause of symptoms and poor asthma control, and leverages this information to build personalized, predictive risk models for each patient.

myBiometry provides actionable insights and delivers guideline-based coaching and education to improve self-management. Their educational programs are scalable to millions of patients and are recognized by the CDC for improving asthma control and reducing costs. While their technology and products are currently under development and not yet approved by the FDA, myBiometry is actively working to bring their innovative solutions to the market.

myBiometry is a company developing a platform to help patients manage their asthma. Their patented sensor and device measures airway inflammation in breath to biologically determine risk of attack, adherence, efficacy of medication, and exposure to environmental triggers. They use this data to create personalized, predictive risk models and deliver actionable insights to patients, enabling them to proactively manage their asthma and reduce the risk of attacks.

The company promotes a culture of innovation and collaboration, focused on empowering patients to improve their asthma control. They emphasize data-driven insights, leveraging technology and personalized risk models to proactively engage patients and deliver self-management education. This focus on patient empowerment and scientific rigor suggests a culture that values both technological advancement and a strong commitment to improving patient outcomes.